Equities

Inotiv Inc

Inotiv Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)3.41
  • Today's Change0.20 / 6.23%
  • Shares traded755.63k
  • 1 Year change+47.62%
  • Beta3.5415
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Inotiv, Inc. is a contract research company, which is engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. The RMS segment offer access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.

  • Revenue in USD (TTM)501.06m
  • Net income in USD-99.22m
  • Incorporated1975
  • Employees1.96k
  • Location
    Inotiv Inc2701 Kent AveWEST LAFAYETTE 47906-1350United StatesUSA
  • Phone+1 (317) 463-4527
  • Fax+1 (765) 497-1102
  • Websitehttps://www.inotivco.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Relmada Therapeutics Inc0.00-86.49m82.98m20.00--1.74-----2.87-2.870.001.580.00----0.00-104.91---116.60--------------0.00------37.09------
PMV Pharmaceuticals Inc0.00-51.47m83.31m63.00--0.421-----0.9998-0.99980.003.820.00----0.00-21.24-21.16-22.36-21.91------------0.00------5.94--16.31--
Fibrobiologics Inc0.00-17.78m83.53m10.00--29.87-----0.8864-0.88640.000.08070.00----0.00-149.60---225.38--------------0.0403-------272.15------
Invivyd Inc11.56m-225.14m83.59m94.00--1.01--7.23-1.95-1.950.09960.69530.0529--2.48123,021.30-103.08---135.83--92.27---1,946.87--1.58--0.00------17.68------
MDxHealth SA80.74m-40.80m84.64m300.00------1.05-1.54-1.543.06-0.32290.59069.397.49269,136.70-29.85-51.62-43.63-64.7262.6450.88-50.54-117.640.8252-1.741.18--89.4319.842.14--30.13--
Genelux Corp8.00k-27.66m84.96m23.00--2.54--10,619.66-0.9537-0.95370.00030.97030.0002----347.83-74.41---92.15-------345,750.00------0.00---98.46---443.44------
Generation Bio Co18.58m-145.47m88.17m174.00--0.8437--4.74-2.19-2.190.27971.560.059--56.31106,793.10-46.16-36.96-51.29-39.21-----782.87-8,879.44----0.00----177.317.34--19.61--
Inotiv Inc501.06m-99.22m88.69m1.96k--0.487--0.177-3.84-3.8419.447.000.6158.126.83256,297.70-12.11-23.84-19.28-29.2624.9329.31-19.70-33.240.2279-0.62340.6774--4.5285.1068.80--83.64--
Quince Therapeutics Inc0.00-53.26m90.02m32.00--2.00-----1.25-1.250.001.040.00----0.00-50.27-42.72-52.16-46.06------------0.249------39.25---5.47--
Hillevax Inc0.00-150.28m90.65m90.00--0.4886-----3.09-3.090.003.730.00----0.00-51.15---54.17--------------0.00------22.68------
Cabaletta Bio Inc0.00-104.16m91.35m154.00--0.5243-----2.17-2.170.003.570.00----0.00-55.16-33.76-60.53-35.68------------0.00-------27.75------
Regulus Therapeutics Inc0.00-41.63m91.70m32.00--1.06-----1.08-1.080.001.330.00----0.00-63.31-53.74-71.29-76.96-------715.58----0.00-------6.05--94.54--
Oramed Pharmaceuticals, Inc.0.004.47m93.12m15.0023.130.593720.21--0.09990.09990.003.890.00----0.002.22--2.79--------------0.00---50.43--115.11------
Assembly Biosciences Inc28.33m-40.80m93.56m65.00--3.60--3.30-7.54-7.545.144.090.373----435,784.60-53.73-39.69-79.14-44.03-----144.05-409.24----0.00-----13.5134.23---5.59--
Annovis Bio Inc0.00-40.94m93.68m6.00--12.77-----3.76-3.760.000.53180.00----0.00-333.05-106.31-523.91-124.71-----------3.510.00-------121.90------
Data as of Nov 21 2024. Currency figures normalised to Inotiv Inc's reporting currency: US Dollar USD

Institutional shareholders

10.32%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 20241.05m4.02%
Columbia Management Investment Advisers LLCas of 30 Sep 2024268.09k1.03%
Geode Capital Management LLCas of 30 Sep 2024250.90k0.97%
Kentucky Planning Partners LLCas of 30 Sep 2024237.72k0.91%
BlackRock Fund Advisorsas of 30 Sep 2024209.27k0.81%
D. E. Shaw & Co. LPas of 30 Sep 2024187.08k0.72%
Renaissance Technologies LLCas of 30 Sep 2024171.06k0.66%
Newton Investment Management North America LLCas of 30 Sep 2024114.10k0.44%
Oak Family Advisors LLCas of 30 Sep 2024108.29k0.42%
Mariner LLCas of 30 Sep 202492.32k0.36%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.